## **Udit Singhal**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4276796/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics, 2015, 47, 199-208.	21.4	2,410
2	Long Noncoding RNAs in Cancer: From Function to Translation. Trends in Cancer, 2015, 1, 93-109.	7.4	218
3	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. Translational Oncology, 2020, 13, 100747.	3.7	36
4	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Molecular Cancer Research, 2018, 16, 643-654.	3.4	33
5	Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. Neoplasia, 2019, 21, 802-809.	5.3	32
6	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 415.e1-415.e6.	1.6	18
7	Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. JAMA Network Open, 2019, 2, e187765.	5.9	17
8	Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. World Journal of Urology, 2022, 40, 35-42.	2.2	13
9	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. Urology, 2022, 164, 184-190.	1.0	8
10	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-NaÃ <sup>-</sup> ve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). International Journal of Molecular Sciences, 2022, 23, 4.	4.1	6
11	Implementation of patient-reported outcome measures into health care for men with localized prostate cancer. Nature Reviews Urology, 2022, 19, 263-279.	3.8	5
12	Intraoperative Management of an Incidentally Identified Ectopic Ureter Inserting Into the Prostate of a Patient Undergoing Radical Prostatectomy for Prostate Cancer. Medicine (United States), 2015, 94, e1261.	1.0	4
13	Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry. Urology, 2020, 145, 190-196.	1.0	4
14	Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. Urology, 2022, 167, 171-178.	1.0	4
15	Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 797.e1-797.e6.	1.6	3
16	Ureteral Involvement Within an Incarcerated Inguinal Hernia in a Patient With Crossed-fused Renal Ectopia. Urology Case Reports, 2016, 7, 20-22.	0.3	2
17	Overcoming Our Red Dots and Confronting Racism From Patients. JAMA Oncology, 2022, 8, 518.	7.1	1
18	EDITORIAL COMMENT. Urology, 2019, 130, 111-112.	1.0	0

**UDIT SINGHAL** 

#	Article	IF	CITATIONS
19	EDITORIAL COMMENT. Urology, 2019, 126, 82.	1.0	0
20	EDITORIAL COMMENT. Urology, 2020, 146, 187-188.	1.0	0
21	Prognostic significance of perineural invasion in localized prostate cancer Journal of Clinical Oncology, 2015, 33, 30-30.	1.6	0
22	Indentification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC Journal of Clinical Oncology, 2017, 35, 5072-5072.	1.6	0
23	Dissection of primary prostate cancer to determine the clonal origin of synchronous lymph node metastasis Journal of Clinical Oncology, 2020, 38, e17614-e17614.	1.6	0
24	Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis Journal of Clinical Oncology, 2022, 40, 266-266.	1.6	0